{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:24Z","timestamp":1787008584883,"version":"build-2736575974"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare genetic disorders characterized by accumulation of protoporphyrin IX (PPIX), painful phototoxic reactions and hepatobiliary disease. No disease-modifying therapies are approved for these conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of bitopertin in adults and adolescents with EPP or XLP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BEACON (ACTRN12622000799752) was a phase II, randomized, open-label, parallel-arm study in adult and adolescent participants with EPP or XLP. Participants received an oral, once-daily administration of bitopertin 20\u2005mg or 60\u2005mg for 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six participants were randomized to 20\u2005mg (n = 14) or 60\u2005mg (n = 12) of bitopertin. The study met its primary efficacy endpoint. Treatment with bitopertin resulted in significant, dose-dependent reductions in PPIX levels compared with baseline at both the 20-mg and 60-mg dose levels (mean \u221231.7%, SE 7.0; P &amp;lt; 0.001 vs. baseline and mean \u221257.7%, SE 7.4; P &amp;lt; 0.001 vs. baseline, respectively). Similar efficacy was observed across the adult and adolescent populations. No serious adverse events were reported. Dizziness was the most common adverse event reported with bitopertin, in 9 (64%)\u00a0and\u00a08 (67%) participants completing the study in the 20-mg and 60-mg dose groups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By reducing whole-blood PPIX levels, bitopertin targets the underlying pathophysiology of EPP, resulting in consistent improvements in multiple measures of light tolerance and quality of life. Bitopertin was well tolerated, and most adverse events were mild or moderate in severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag002","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:32:55Z","timestamp":1768048375000},"page":"1020-1027","source":"Crossref","is-referenced-by-count":3,"title":["An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-1920","authenticated-orcid":false,"given":"Gayle","family":"Ross","sequence":"first","affiliation":[{"name":"Dermatology, Royal Melbourne Hospital , Parkville, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stewart","sequence":"additional","affiliation":[{"name":"Chemical Pathology RPAH, Royal Prince Alfred Hospital , Camperdown, Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mensing","sequence":"additional","affiliation":[{"name":"Clinical Development, Bioanalytical and Nonclinical Operations, Disc Medicine , Watertown, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Chin","sequence":"additional","affiliation":[{"name":"Clinical Development, Bioanalytical and Nonclinical Operations, Disc Medicine , Watertown, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Howell","sequence":"additional","affiliation":[{"name":"Clinical Development, Bioanalytical and Nonclinical Operations, Disc Medicine , Watertown, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Mangus","sequence":"additional","affiliation":[{"name":"Clinical Development, Bioanalytical and Nonclinical Operations, Disc Medicine , Watertown, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Savage","sequence":"additional","affiliation":[{"name":"Clinical Development, Bioanalytical and Nonclinical Operations, Disc Medicine , Watertown, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026052522563759500_llag002-B1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymgme.2019.01.020","article-title":"Erythropoietic protoporphyria and X-linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management","volume":"128","author":"Balwani","year":"2019","journal-title":"Mol Genet Metab"},{"key":"2026052522563759500_llag002-B2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2119\/molmed.2012.00340","article-title":"Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria","volume":"19","author":"Balwani","year":"2013","journal-title":"Mol Med"},{"key":"2026052522563759500_llag002-B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/diagnostics12010151","article-title":"Recognized and emerging features of erythropoietic and X-linked protoporphyria","volume":"12","author":"Di Pierro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026052522563759500_llag002-B4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","article-title":"Heme biosynthesis and the porphyrias","volume":"128","author":"Phillips","year":"2019","journal-title":"Mol Genet Metab"},{"key":"2026052522563759500_llag002-B5","first-page":"9","article-title":"Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria","volume":"50","author":"Naik","year":"2019","journal-title":"JIMD Rep"},{"key":"2026052522563759500_llag002-B6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamadermatol.2017.1557","article-title":"Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria","volume":"153","author":"Balwani","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2026052522563759500_llag002-B7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-4-19","article-title":"Erythropoietic protoporphyria","volume":"4","author":"Lecha","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"2026052522563759500_llag002-B8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41436-020-00951-8","article-title":"Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria","volume":"23","author":"Dickey","year":"2021","journal-title":"Genet Med"},{"key":"2026052522563759500_llag002-B9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","article-title":"The incidence of inherited porphyrias in Europe","volume":"36","author":"Elder","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"2026052522563759500_llag002-B10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N Engl J Med"},{"key":"2026052522563759500_llag002-B11","doi-asserted-by":"crossref","first-page":"101928","DOI":"10.1016\/j.pdpdt.2020.101928","article-title":"Trends in erythrocyte protoporphyrin IX concentration by age, sex and season among patients with erythropoietic protoporphyria \u2013 20\u2005years of follow-up","volume":"32","author":"Heerfordt","year":"2020","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2026052522563759500_llag002-B12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2796.2010.02236.x","article-title":"Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics","volume":"269","author":"Wahlin","year":"2011","journal-title":"J Intern Med"},{"key":"2026052522563759500_llag002-B13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.dld.2021.08.007","article-title":"Liver involvement in patients with erythropoietic protoporphyria","volume":"54","author":"Wensink","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026052522563759500_llag002-B14","doi-asserted-by":"crossref","first-page":"8192","DOI":"10.1182\/blood-2022-168924","article-title":"Bitopertin, a selective glycine transporter 1 inhibitor, reduced protoporphyrin IX (PPIX) level and improved liver fibrosis in a mouse model of erythropoietic protoporphyria (EPP)","volume":"140","author":"Wu","year":"2022","journal-title":"Blood"},{"key":"2026052522563759500_llag002-B15","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2024-208017","article-title":"Inhibition of glycine transporter 1 reduces EPP phototoxicity in a mouse model of erythropoietic protoporphyria","volume":"144","author":"Xiang","year":"2024","journal-title":"Blood"},{"key":"2026052522563759500_llag002-B16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s41687-023-00655-y","article-title":"Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria","volume":"7","author":"Mathias","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"2026052522563759500_llag002-B17","author":"Roche"},{"key":"2026052522563759500_llag002-B18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10928-025-09990-7","article-title":"A semi-mechanistic population pharmacokinetic\u2013pharmacodynamic model to assess downstream drug-target effects on erythropoiesis","volume":"52","author":"Rogn\u00e5s","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026052522563759500_llag002-B19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4155\/ipk-2016-0001","article-title":"Pharmacokinetic considerations when prescribing in children","volume":"1","author":"Eidelman","year":"2016","journal-title":"Int J Pharmacokinet"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag002\/66382597\/llag002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1020\/66382597\/llag002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1020\/66382597\/llag002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:56:46Z","timestamp":1779764206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/1020\/8423544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag002","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,13]]}}}